Genflow Biosciences PLC Announces Total Voting Rights
LONDON, UK / ACCESS Newswire / October 31, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company"), an emerging...
Clinical Trial
Hemostemix’s Boots on the Ground in Florida October Update
Calgary, Alberta--(Newsfile Corp. - October 30, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's...
Saama Unveils Industry-first AI-Powered Tables, Listings, and Figures (TLF) Analyzer to Transform Clinical Study Reporting
New multi-modal GenAI solution accelerates report authoring and introduces breakthrough "Figures-to-Text" interpretation for faster, context-aware clinical insights CAMPBELL, Calif., Oct....
Signant Health Appoints Internationally Recognized Cognitive Assessment Expert John Harrison to Further Advance Innovation in CNS Clinical Trials
PHILADELPHIA, Oct. 30, 2025 /PRNewswire/ -- Signant Health, the leader in evidence generation for modern clinical trials, announced today the...
Merigold and Log10 Announce Partnership to Power Bloom AI — Accelerating Medical Writing with Generative AI
Merigold and Log10 partner to apply Everest's AI technology to the multibillion-dollar imaging clinical trials market, debuting Bloom AI at...
Intensity Therapeutics, Inc. Announces Publication of Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers in eBioMedicine, a Lancet Discovery Science Journal
The paper features a comprehensive evaluation of data, including disease control rate, overall survival, immune activation, abscopal effects, tumor necrosis,...
Moleculin to Highlight its Ongoing Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial at the 14th Annual Acute Leukemia Meeting
HOUSTON, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company...
Akari Therapeutics Announces Formation of Scientific Advisory Board and Inaugural Appointment of Renowned Medical Oncologist, Sara A. Hurvitz, MD, FACP
Dr. Hurvitz is an international expert in oncology and a recognized clinical research leader with extensive experience leading clinical trials...
Neuronetics Announces Three-Year Exclusive Partnership with Elite DNA Behavioral Health to Expand NeuroStar Access and Operational Excellence
New collaboration provides services to streamline patient support, reduce administrative burden, and expand access to advanced TMS treatment across Elite...
Aligos Therapeutics to Announce 3rd Quarter 2025 Financial Results on November 6, 2025
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company...
ALX Oncology to Report Third Quarter 2025 Financial Results and Pipeline Progress Including Evorpacept CD47 Biomarker Data to be Presented at Upcoming SITC Annual Meeting
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq:...
Ritedose Now Offers the Largest Nebulized Drug Portfolio in the U.S.: FDA Approves the Company to Manufacture Generic Tobramycin Inhalation Solution
Ritedose receives FDA approval for Tobramycin Tobramycin expands nation's largest nebulized drug portfolio. - Generic Tobramycin Inhalation Solution marks the...
Evaxion raises $7.2 million, extending cash runway to second half of 2027
Gross proceeds from sales of shares amounting to $4.5 million and exercise of warrants providing a further $2.7 millionTotal gross...
T-knife Therapeutics Announces Four Upcoming Data Presentations on PRAME-Targeted TK-6302 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
-- Posters will review product characterization and manufacturing data on T-knife’s lead program, TK-6302, a supercharged PRAME T cell receptor...
Arcutis Launches ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Children Ages 2 to 5
Once-daily, effective, safe, and well-tolerated ZORYVE cream 0.05% now commercially available for children as young as age 2ZORYVE cream 0.05%...
BioCardia Announces University of Wisconsin Enrolls Their First Patient in Phase 3 CardiAMP HF II Cell Therapy Pivotal Trial
SUNNYVALE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. , a global leader in cellular and cell-derived therapeutics for the...
New Clinical and Translational Data on PDS Biotechnology’s Novel Investigational Cancer Therapies PDS0101 and PDS01ADC to be Presented at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Three abstracts accepted for presentation, including one rapid oral abstract sessionPresentations to highlight ongoing clinical and translational research across PDS...
Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025
BASKING RIDGE, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage...
Humacyte Announces Publication of New Data Comparing Symvess™ to Autologous Vein in Extremity Arterial Trauma
- Results published in AAST’s Trauma Surgery & Acute Care Open Journal - - Study compared outcomes of patients treated...
BioNxt Reports “Readiness to Grant” Patent Notification from the Eurasian Patent Organization
VANCOUVER, BC / ACCESS Newswire / October 30, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience...